StocksMedium•10 November 2026•
1 min read
Opus Genetics Reports Wider-than-Expected Q3 Loss
Key Facts
1Opus Genetics reported a Q3 loss of $0.18 per share, wider than the Zacks Consensus Estimate of a $0.14 loss.
Opus Genetics reported a loss of $0.18 per share for the third quarter of 2026. Zacks reported that this figure was wider than the consensus estimate of a $0.14 loss and compared unfavorably to the prior year's loss of $0.12 per share.
IRD closed at $4.2 on November 9, 2026, prior to the release of the third-quarter results which confirmed the company missed revenue estimates. The stock traded between a low of $4.15 and a high of $4.37 on that date.